IMMUNITYBIO, INC. Net Income (Loss) Available to Common Stockholders, Diluted
IMMUNITYBIO, INC. (IBRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$230.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-04
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$230.38M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$632.78M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$61.94M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$67.25M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$351.40M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$433.49M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$583.20M.
- IMMUNITYBIO, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$416.57M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$230.38M 10-Q · filed 2026-08-04 | -$863.16M 10-Q · filed 2026-08-04 | -$925.10M derived: sum of 3 quarters · filed 2026-08-04 | -$992.36M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$632.78M 10-Q · filed 2026-05-07 | -$694.73M derived: sum of 2 quarters · filed 2026-05-07 | -$761.98M derived: sum of 3 quarters · filed 2026-05-07 | -$854.53M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$61.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$129.20M derived: sum of 2 quarters · filed 2026-02-23 | -$221.75M derived: sum of 3 quarters · filed 2026-08-04 | -$351.40M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$67.25M 10-Q · filed 2025-11-05 | -$159.81M derived: sum of 2 quarters · filed 2026-08-04 | -$289.45M 10-Q · filed 2025-11-05 | -$357.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$92.56M 10-Q · filed 2026-08-04 | -$222.20M 10-Q · filed 2026-08-04 | -$290.73M derived: sum of 3 quarters · filed 2026-08-04 | -$390.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$129.65M 10-Q · filed 2026-05-07 | -$198.18M derived: sum of 2 quarters · filed 2026-05-07 | -$298.41M derived: sum of 3 quarters · filed 2026-05-07 | -$432.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$68.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$168.76M derived: sum of 2 quarters · filed 2026-02-23 | -$303.33M derived: sum of 3 quarters · filed 2026-02-23 | -$433.49M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$100.23M 10-Q · filed 2025-11-05 | -$234.80M derived: sum of 2 quarters · filed 2025-11-05 | -$364.95M 10-Q · filed 2025-11-05 | -$602.30M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$134.56M 10-Q · filed 2025-08-05 | -$268.67M 10-Q · filed 2025-08-05 | -$502.06M derived: sum of 3 quarters · filed 2026-02-23 | -$597.65M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$134.11M 10-Q · filed 2025-05-12 | -$367.50M derived: sum of 2 quarters · filed 2026-02-23 | -$463.08M derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$233.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$328.97M derived: sum of 2 quarters · filed 2026-02-23 | -$583.20M 10-K · filed 2026-02-23 | |
| 2023-09-30 | -$95.58M 10-Q · filed 2024-11-12 | -$349.80M 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | -$416.57M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |